Widely used:Recently Viewed
Clear All$70.95
$-0.76
(-1.06%)
As on 28-Apr-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$7,574 Mln
P/E Ratio
58.3
P/B Ratio
11.13
Industry P/E
--
Debt to Equity
0.01
ROE
0.24 %
ROCE
23.42 %
Div. Yield
0 %
Book Value
5.99
EPS
1.23
CFO
$874.09 Mln
EBITDA
$719.20 Mln
Net Profit
$695.14 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
| 40.80 | 25.18 | 17.66 | 211.18 | 48.74 | 39.40 | 27.62 |
|
BSE Sensex*
| 2.75 | 3.85 | 5.92 | 9.04 | 11.81 | 20.15 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
| 54.59 | 59.92 | 2.58 | -24.31 | 116.20 | -9.43 | -25.90 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 24.51 | 5,327.13 | 26.99 | 81.65 | |
| 35.89 | 6,904.81 | -- | 38.11 | |
| 59.52 | 11,448.88 | 394.4 | 0.76 | |
| 8.25 | 9,704.70 | -- | -3.24 |
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the... treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California. Address: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065 Read more
Co-Founder, President, CEO & Director
Dr. Joseph K. Belanoff M.D.
Co-Founder, President, CEO & Director
Dr. Joseph K. Belanoff M.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Corcept Therapeutics Incorporated (CORT) stood at $ 841 Mln as on 31-Dec-24
The share price of Corcept Therapeutics Incorporated (CORT) is $70.95 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Corcept Therapeutics Incorporated (CORT) has given a return of 48.74% in the last 3 years.
Corcept Therapeutics Incorporated (CORT) has a market capitalisation of $ 7,574 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Corcept Therapeutics Incorporated (CORT) is 58.30 times as on 28-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Corcept Therapeutics Incorporated (CORT) and enter the required number of quantities and click on buy to purchase the shares of Corcept Therapeutics Incorporated (CORT).
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California. Address: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
The CEO & director of Dr. Joseph K. Belanoff M.D.. is Corcept Therapeutics Incorporated (CORT), and CFO & Sr. VP is Dr. Joseph K. Belanoff M.D..
There is no promoter pledging in Corcept Therapeutics Incorporated (CORT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
670
|
|
|
518
|
| Corcept Therapeutics Incorporated (CORT) | Ratios |
|---|---|
|
Return on equity(%)
|
23.56
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
20.7
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Corcept Therapeutics Incorporated (CORT) was $0 Mln.
